AMBIGUOUS RESULTS

Annexon frames Phase 2 vonaprument vision data as blueprint for pivotal Phase 3

ARCHER hit vision-preservation measures and photoreceptor protection, but the press release omitted the trial's own registered endpoint, GA lesion growth rate, ahead of Phase 3 ARCHER II data due in Q4 2026.

By AppliedXLJuly 14, 2026Trial NCT04656561

Executive Summary

Annexon reported that its Phase 2 trial showed statistically significant protection against vision loss and photoreceptor degeneration through twelve months, but the release did not address the trial's own registered anatomical endpoint.
The company is using this functional and structural data to justify how it selected patients for the ongoing pivotal trial, rather than presenting it as a fresh registrational result.
The endpoint the trial was actually designed and registered to measure went unaddressed in the disclosure, leaving the functional-vision story incomplete against the trial's own design.
No other industry-sponsored trial combines this mechanism with this disease at this stage, so there is no same-class precedent against which to weigh the result.
The pivotal trial has already finished enrollment, and its topline result will be the test of whether this functional signal translates into a registrable outcome.

The disclosure

Annexon, Inc. said its Phase 2 ARCHER trial (NCT04656561) showed vonaprument produced "statistically significant, time and dose-dependent protection from vision loss as measured by confirmed best corrected visual acuity (BCVA) ≥15-letter loss, the widely accepted and clinically meaningful functional endpoint". The company also reported gains on low luminance visual acuity and low luminance visual deficit, along with photoreceptor protection measured by optical coherence tomography. Safety was described as favorable through month 12, with no increase in choroidal neovascularization between the treated and sham arms and no retinal vasculitis events. The trial enrolled 270 patients across the United States, Australia and New Zealand and completed in 2024 after reaching its enrollment target. Annexon+1

What the trial was built to measure

ARCHER's own registered primary outcome measure was GA lesion growth rate, an anatomical measure of how fast the area of retinal atrophy expands. The July 14 release does not address that measure, framing the result instead around functional vision endpoints and OCT-based photoreceptor protection. That gap matters because GA lesion growth rate, not visual acuity, was the metric ARCHER was designed and powered to test. NCT04656561+1

Why the framing matters now

The release ties the ARCHER data directly to an upcoming oral presentation at the American Society of Retina Specialists meeting on July 18, 2026, describing baseline characteristics associated with BCVA loss as informing "patient population selection for the ongoing Phase 3 ARCHER II trial". ARCHER II is a 659-patient, sham-controlled, double-masked pivotal trial that completed enrollment in July 2025, with topline data expected in the fourth quarter of 2026. Annexon is using the Phase 2 vision-function results to explain how it built the pivotal trial's population, rather than presenting them as a new standalone efficacy claim. Annexon

Registry history

ARCHER's registry record shows a status regression from Recruiting back to Not yet recruiting in February 2021, a primary completion date pushed from June 1 to June 30, 2023 alongside an enrollment increase from 240 to 270 patients in July 2022, and a stretch of Unknown status beginning June 2024 before the trial was marked Completed in August 2024. The trial's actual primary completion occurred in March 2023, roughly seventeen months before the registry reflected its completed status. NCT04656561

Competitive and regulatory context

No other industry-sponsored trial pairs C1q inhibition with geographic atrophy at Phase 2 or later; ARCHER is the only trial in that combination on record. Vonaprument holds FDA Fast Track designation and was the first candidate for geographic atrophy to receive EMA PRIME designation. Other geographic atrophy programs in development use different mechanisms, including Regeneron's C5-targeting cemdisiran and Belite Bio's RBP4-targeting tinlarebant, both in Phase 3, meaning vonaprument's classical-complement approach has no mechanism-matched precedent to benchmark against in this disease. Annexon

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.